Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model

被引:4
作者
Choi, Joongwon [1 ]
Jung, Tae Young [2 ]
Kim, Jung Hoon [1 ]
Maeng, Sejung [3 ]
Kang, Su Jeong [3 ]
Kim, Mirinae [3 ]
Choi, Young Wook [3 ]
Choi, Se Young [3 ]
Kim, Sung-Hwan [4 ]
Chang, In Ho [3 ,5 ]
机构
[1] Chung Ang Univ, Gwangmyeong Hosp, Coll Med, Dept Urol, Gwangmyeong, South Korea
[2] VHS Med Ctr, Dept Urol, Seoul, South Korea
[3] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Urol, Seoul, South Korea
[4] Cellsmith Inc, Seoul, South Korea
[5] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Urol, 102 Heukseok Ro, Seoul 06973, South Korea
基金
新加坡国家研究基金会;
关键词
Bioprinting; Mycobacterium bovis; Tumor microenvironment; BCG; ASSOCIATION; MANAGEMENT; CARCINOMA; THERAPIES; CELLS;
D O I
10.4111/icu.20220293
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We investigated the efficacy and optimal dosage of recombinant Bacillus Calmette-Guerin-dltA (rBCG-dltA) in a high-throughput 3D bio-printed bladder cancer-on-a-chip (BCOC) and orthotopic bladder cancer mouse model.Materials and Methods: We fabricated high-throughput BCOC with microfluidic systems, enabling efficient drug screening. The efficacy of rBCG-dltA was evaluated using BCOC by the cell viability assay, monocyte migration assay, and measuring cytokine levels. The anti-tumor effect was compared using the orthotopic bladder cancer mouse model.Results: The cell proliferation rates of T24 and 253J bladder cancer cell lines (mean +/- standard error) were measured at three days after treatment. In T24 cell line, there was significantly decreased T24 cells compared to control at rBCG 1 multiplicity of infection (MOI) and 10 MOI (30 MOI: 63.1 +/- 6.4, 10 MOI: 47.4 +/- 5.2, 1 MOI: 50.5 +/- 7.5, control: 100.0 +/- 14.5, p<0.05). In 253J cell line, a statistically significant decrease in 253J cell count compared to control and mock BCG 30 MOI (30 MOI: 11.2 +/- 1.3, 10 MOI: 22.5 +/- 2.3, 1 MOI: 39.4 +/- 4.7,Mock: 54.9 +/- 10.8, control: 100.0 +/- 5.6, p<0.05). The migration rates of THP-1 cells showed increased patterns after rBCG-dltA treatment in BCOC. The concentration of tumor necrosis factor-alpha and interleukin-6 after rBCG-dltA 30 MOI treatment was higher than control in T24 and 253J cell line.Conclusions: In conclusion, rBCG-dltA has the potential to have better anti-tumor activity and immunomodulatory effects than BCG. Furthermore, high-throughput BCOCs have potential to reflect the bladder cancer microenvironment.
引用
收藏
页码:296 / 305
页数:10
相关论文
共 30 条
[1]   European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update [J].
Babjuk, Marko ;
Burger, Maximilian ;
Comperat, Eva M. ;
Gontero, Paolo ;
Mostafid, A. Hugh ;
Palou, Joan ;
van Rhijn, Bas W. G. ;
Roupret, Morgan ;
Shariat, Shahrokh F. ;
Sylvester, Richard ;
Zigeuner, Richard ;
Capoun, Otakar ;
Cohen, Daniel ;
Dominguez Escrig, Jose Luis ;
Hernandez, Virginia ;
Peyronnet, Benoit ;
Seisen, Thomas ;
Soukup, Viktor .
EUROPEAN UROLOGY, 2019, 76 (05) :639-657
[2]   EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin [J].
Cambier, Samantha ;
Sylvester, Richard J. ;
Collette, Laurence ;
Gontero, Paolo ;
Brausi, Maurizio A. ;
van Andel, George ;
Kirkels, Wim J. ;
Da Silva, Fernando Calais ;
Oosterlinck, Willem ;
Prescott, Stephen ;
Kirkali, Ziya ;
Powell, Philip H. ;
de Reijke, Theo M. ;
Turkeri, Levent ;
Collette, Sandra ;
Oddens, Jorg .
EUROPEAN UROLOGY, 2016, 69 (01) :60-69
[3]   Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline [J].
Chang, Sam S. ;
Boorjian, Stephen A. ;
Chou, Roger ;
Clark, Peter E. ;
Daneshmand, Siamak ;
Konety, Badrinath R. ;
Pruthi, Raj ;
Quale, Diane Z. ;
Ritch, Chad R. ;
Seigne, John D. ;
Skinner, Eila Curlee ;
Smith, Norm D. ;
McKiernan, James M. .
JOURNAL OF UROLOGY, 2016, 196 (04) :1021-1029
[4]   Emerging intravesical therapies for the management of bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward [J].
Chehroudi, Ali Cyrus ;
Black, Peter C. .
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (06) :204-213
[5]   The immunotherapeutic effects of recombinant Bacillus Calmette-Guerin resistant to antimicrobial peptides on bladder cancer cells [J].
Cho, Min-Ji ;
Kim, Myeong Joo ;
Kim, Kijeong ;
Choi, Young Wook ;
Lee, Sang-Jin ;
Whang, Young Mi ;
Chang, In Ho .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 509 (01) :167-174
[6]   Modulating the Internalization of Bacille Calmette-Guerin by Cathelicidin in Bladder Cancer Cells [J].
Choi, Se Young ;
Kim, Soon-Ja ;
Chi, Byung Hoon ;
Kwon, Jong Kyou ;
Chang, In Ho .
UROLOGY, 2015, 85 (04) :964.e7-964.e12
[7]   Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin [J].
Dinney, Colin P. N. ;
Greenberg, Richard E. ;
Steinberg, Gary D. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) :1635-1642
[8]  
Du Liqin, 2014, F1000Res, V3, P106, DOI 10.12688/f1000research.4097.1
[9]   The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside [J].
Duplisea, Jonathan J. ;
Mokkapati, Sharada ;
Plote, Devin ;
Schluns, Kimberly S. ;
McConkey, David J. ;
Yla-Herttuala, Seppo ;
Parker, Nigel R. ;
Dinney, Colin P. .
WORLD JOURNAL OF UROLOGY, 2019, 37 (10) :2041-2049
[10]   Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer [J].
Jamil, Marcus L. ;
Deebajah, Mustafa ;
Sood, Akshay ;
Robinson, Kathy ;
Rao, Krishna ;
Sana, Sherjeel ;
Alanee, Shaheen .
BMJ OPEN, 2019, 9 (07)